Memantine transdermal delivery systems
View Patent ↗Transdermal delivery systems for the systemic delivery of memantine are described, wherein the system comprises a drug reservoir layer and an adhesive layer, optionally together with one or more intermediate and/or supporting layers, wherein the drug reservoir layer comprises an acrylate polymer or copolymer, a permeation enhancer, a carrier, and memantine base generated in situ by reaction of a memantine salt and an alkaline salt. Compositions and kits comprising the various components, e.g., drug reservoir and/or adhesive compositions are described. Methods relating to treatment of CNS disorders, e.g., Alzheimer's disease and/or dementia, using the aforementioned transdermal delivery devices and/or compositions are also described.
1. A composition, comprising: a drug reservoir consisting essentially of a salt of memantine and an alkaline salt; a permeation enhancer; a hydrophilic solvent carrier; a crosslinked polyvinylpyrrolidone; and an acrylate copolymer, wherein, after application of the composition to the skin of a subject, memantine base is generated in situ by reaction of the salt of memantine and the alkaline salt.
2. The composition of claim 1 , wherein the hydrophilic solvent carrier is glycerol.
3. The composition of claim 1 , wherein the permeation enhancer is a higher alcohol selected from the group consisting of lauryl alcohol, isostearyl alcohol, octyldodecanol, and oleyl alcohol.
4. The composition of claim 1 , wherein the salt of memantine is memantine hydrochloride and the alkaline salt is selected from the group consisting of sodium acetate, sodium borate, sodium metaborate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium citrate, potassium acetate, sodium phosphate, potassium phosphate, disodium hydrogen phosphate, sodium oxylate, sodium succinate, sodium citrate, and sodium salicylate.
5. The composition of claim 1 , further comprising a skin contact adhesive comprised of polyisobutylene (PIB), polybutylene, or a mixture thereof.
6. The composition of claim 5 , wherein the skin contact adhesive comprises (i) about 5-15 wt % octyldodecanol; (ii) a mixture of polyisobutylene and polybutylene; and optionally (iii) about 10-30 wt % cross-linked PVP.
7. The composition of claim 5 , wherein the skin contact adhesive comprises, (i) about 8-12 wt % octyldodecanol; (ii) about 65-90 wt % of a mixture of polyisobutylene and polybutylene; and optionally (iii) about 15-25 wt % cross-linked PVP.
8. The composition of claim 1 , wherein memantine base is generated in situ in the drug reservoir over a 3-5 day period.
9. The composition of claim 1 , wherein the salt of memantine is memantine hydrochloride and the alkaline salt is sodium bicarbonate.
10. The composition of claim 9 , wherein the drug reservoir comprises a molar amount of memantine hydrochloride and an equimolar or less than less than equimolar amount of sodium bicarbonate.
11. The composition of claim 10 , wherein the drug reservoir comprises between about 10-30 wt % memantine hydrochloride.
12. The composition of claim 10 , wherein the drug reservoir comprises between about 22-27 wt % memantine hydrochloride.
13. The composition of claim 10 , wherein the drug reservoir comprises between about 5-15 wt % sodium bicarbonate.
14. A composition, comprising: a drug reservoir consisting essentially of
(a) between about 10-30 wt % memantine HCl and between about 5-15 wt % sodium bicarbonate;
(b) about 5-15 wt % octyldodecanol;
(c) about 5-15 wt % glycerol;
(d) about 10-30 wt % crosslinked polyvinylpyrrolidone; and
(e) about 20-50 wt % acrylate polymer, wherein, after application of the composition to the skin of a subject, memantine base is generated in situ by reaction of the memantine HCl and the sodium bicarbonate.
15. A method for delivering memantine to a subject in need thereof, comprising:
administering the composition of claim 1 to the skin of a human subject, whereby said administering achieves transdermal delivery of memantine base to the subject.
16. The method of claim 15 , wherein the subject is suffering from or has been diagnosed with a CNS disorder.
17. The method of claim 16 , wherein the CNS disorder is Alzheimer's disease.